CD1D and neoplasm: The CAR/TCR/NKR triple-targeting mechanisms of Allo15BCAR-NKT cells were further validated using a series of in vitro tumor cell killing assays (Fig. 2f–n), involving three human MM.1S-derived cell lines as targets (MM-FG-CD1d that was BCMA+CD1d+, MM-FG that was BCMA+CD1d− and KOMM-FG that was BCMA−CD1d−) and four therapeutic cells (Allo15BCAR-NKT cells, and three controls cells: PBMC-T, BCAR-T and AlloNKT) (Fig. 2f–h and Supplementary Fig. 7a–c).